Association between "sarcoidosis-like" disease and common variable immunodeficiency (CVI): A new CVI variant showing an activation of the immune system

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 24, Issue 2, 2007, Pages 127-133

  Vultaggio, Alessandra ^a   Matucci, Andrea ^a   Parronchi, Paola ^b   Rossi, Oliviero ^a   Filì, Lucia ^a   Giudizf, Maria Grazia ^b   Palandri, Francesco ^a   Agostini, Carlo ^c   Semenzato, Gianpietro ^c   Romagnani, Sergio ^b   Maggi, Enrico ^a,b  

^a AOUC   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bronchoalveolar lavage; Common variable immunodeficiency, globulins; Cytokines; Granulomatous diseases; Sarcoidosis; TNF

Indexed keywords

CARBON MONOXIDE; CHLOROQUINE; COTRIMOXAZOLE; IDROSSICHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; STEROID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BRONCHIECTASIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COMMON VARIABLE IMMUNODEFICIENCY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOPATHOLOGY; LABORATORY TEST; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; LYMPH NODE BIOPSY; MACROPHAGE ACTIVATION; MALE; MONOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SARCOIDOSIS; TUBERCULOSIS;

ADOLESCENT; ADULT; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; SARCOIDOSIS;

EID: 41149140345     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Yamamoto M, Sharma OP, Hosoda Y: Special Report: The 1991 Descriptive Definition of Sarcoidosis. Sarcoidosis 1992; 9: 33-4.
2. Newman LS, Rose CS, Maier LA: Sarcoidosis. N Engl J Med 1997; 336: 1224-34.
3. Spickett GP: Current perspective on common variable immunodeficiency (CVID). Clin. Exp All 2001; 31: 536-42.
4. Moller DR, Forman JD, Liu MC, et al: Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-60.
5. Romagnani S: Role of Th1/Th2 cells in pathophysiologic conditions. In: The Th1/Th2 paradigm in disease Ed. Sprinter R.G. Landes Company Austin, Texas 1997; 109-58.
6. Baughman RP, Stohofer SA, Buchsbaum J, et al: Release of tumor necrosis factor by alveo-lar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42.
7. Agostini C, Trentin L, Facco M, et al: Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996; 157: 910-8.
8. Ballow M: Primary immunodeficiency disorders: antibody deficienc J Allergy Clin Immunol 2002; 109: 581-91.
9. Castigli E, Geha RS: Molecular basis of common variable immunodeficiency. J All Clin Immunol 2006; 117:740-6.
10. Mechanic LJ, Dikman S, Cunningham-Rudles C: Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997; 127: 613-7.
11. Sharma SK, Mohan A: Uncommon manifestations of sarcoidosis. J Assoc Physicians India 2004; 52: 210-4.
12. Fasano MB, Sullivan KE Sarpong SB, et al: Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of literature. Medicine (Baltimore) 1996; 75: 251-61.
13. Agostini C, Semenzato G: Immunodeficienza comune variabile: quai è il legame? Ann Ital Med Int 2002; 17: 77-80.
14. Sideras P, Smith CL: Molecular and cellular aspects of X linked agammaglobulinemia. Adv Immunol 1995; 59: 135-223.
15. Farrant J, Spickett G, Matamoros N, et al: Study of B and T cell phenotypes in blood from patients with common variable immunodeficiency (CVID). Immunodeficinecy 1994; 5: 159-69.
16. Shevach EM: CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2: 389-400.
17. Miyara M, Amoura Z, Parizot C, et al: The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203: 359-70.
18. Fevang B, Yndestad A, Sandberg WJ, et al: Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol 2007; 147: 521-5.
19. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758-765
20. Lories RJ, Casteels-Van Daele M, Ceuppens JL and van Gool SW Polyclonal immunoglobulins for intravenous use induce IL-10 release in vivo and in vitro Ann Rheumat Dis 2004; 63: 747-748)
21. Buckley R, Schiff RI: The use of intravenous immune globulin in immunodeficiency disease. N Engl J Med 1991; 325: 110-7.
22. Baughman RP, Lower EE: Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-4,
23. Yee AM, Pochapin MB: Treatment of complicated sarcoidosis with infliximab and anti-tumor necrosis-alpha neutralizing agent. Annual Intern Med 2001 ; 135: 27-31.
24. Dai H, Guzman J, Chen B, Costabel U: Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alfa by alveolar macrophaghes in sarcoidosis and in extrinsic allergic alveolitis. Chest 2005; 127: 251-6
25. Aukrust P, Lien E, Kristoffersen AK, et al: Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency: possible immunological and clinical consequences. Blood 1996; 87: 674-81.